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Abstract
Background and Objectives: D-negative patients undergoing orthotopic liver transplan-
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tation (OLT) might require a large number of red blood cell (RBC) units, which can impact
the inventory of D-negative blood. The blood bank might need to supply these patients
with D-positive RBCs because of inventory constraints. This study evaluates the prevalence of anti-D formation in D-negative OLT patients who received D-positive RBCs
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perioperatively, as this will assist in successful patient blood management.
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Results: Of a total of 155 D-negative patients, 23 (14.8%) received D-positive RBCs

Materials and Methods: This was a retrospective study performed at a single academic medical centre. Electronic medical records for all 1052 consecutive patients
who underwent OLT from January 2007 through December 2017 were reviewed.
D-negative patients who were transfused perioperatively with D-positive RBCs and
had antibody screening at least 30 days after transfusion were included.
perioperatively. Seventeen patients were included in the study. The median age was
54 years (range 36–67 years); 13 (76.5%) were male. The median number of
D-positive RBC units transfused perioperatively was 7 (range 1–66 units). There was
no evidence of D alloimmunization in any patient after a median serologic follow-up
of 49.5 months (range 31 days to 127.7 months). The average number of antibody
screening post OLT was 7.29.
Conclusion: Our study showed that transfusion of D-positive RBCs in D-negative
OLT recipients is a safe and acceptable practice in the setting of immunosuppression.
This practice allows the conservation of D-negative RBC inventory.
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Highlights
• Owing to increased transfusion demand and inventory constraints, the blood bank might be
forced to transfuse D-positive red blood cells (RBCs) to D-negative patients undergoing liver
transplant.

This work was presented, in part, at the American Association of Blood Banks Annual Meeting, 13–16 October 2018.
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• Our study showed that transfusion of D-positive RBCs to D-negative liver transplant recipients is a safe and acceptable practice perioperatively; none of the studied patients had
alloimmunization to the D antigen.
• The practice of transfusing D-positive RBCs to D-negative liver transplant recipients allows
the conservation of D-negative RBC units for other patients in greater need of this resource.

I N T R O D U CT I O N

period was defined as the period spanning 1 week before OLT until
2 weeks following OLT. Patients who were transfused perioperatively

Liver transplantation has significantly improved the outcomes and life

with D-positive RBCs and had antibody screening at least 30 days

expectancy of patients with end-stage liver disease. Transplant sur-

after the first D-positive RBC transfusion were included in the

geries in general and liver transplants specifically have been associ-

analysis.

ated with significant blood loss and often require intensive

Data collected for each patient included demographic details, clin-

transfusion support with blood products [1]. Advances in surgical

ical history, perioperative RBC transfusion and follow-up antibody

techniques and anaesthetic management have contributed to an over-

screening. Blood bank records were last reviewed in December 2021

all reduction in the transfusion needs during and following liver trans-

for updated antibody screening.

plantation. Despite blood management, liver transplantation is still
associated with high blood transfusion requirements perioperatively
because of abnormal haemostasis and bleeding complications [2, 3].

Blood bank testing

D-negative patients are routinely transfused with D-negative red
blood cells (RBCs) because of the high immunogenicity of the D anti-

ABO and RhD group testing were performed using the following

gen. The rate of alloimmunization to the D antigen in healthy volun-

immunohaematology analysers utilizing solid-phase technology:

teers following transfusion of D-positive packed RBCs can be as high

Galileo (available till 2012), Galileo NEO (2012 to February 2020) and

as 80% [4]. However, immunosuppressed antigen-negative patients

NEO Iris (since March 2020). Manual tube testing was used to resolve

(such as organ transplant recipients and oncology patients) are much

discrepancies in ABO forward and reverse grouping. ABO blood group

less likely to produce an alloantibody when exposed to a foreign RBC

testing was performed using monoclonal anti-A, anti-B and anti-D

antigen [5–7].

antisera for forward typing (Immucor, Norcross, GA) and pooled A1

When D-negative patients undergo liver transplant surgeries, it

and B cells for reverse typing (Immucor). Antibody screening was per-

may not be possible for the blood bank to provide the required num-

formed by indirect antiglobulin test (IAT) using a two-cell screen on

ber of D-negative units because of inventory constraints; thus, the

the same analyser. Positive samples were investigated for antibody

blood bank might transfuse these patients with D-positive RBCs.

identification with a 14-cell panel. All tests were performed according

Though the process of providing D-positive RBCs to D-negative

to manufacturers’ instructions.

transplant recipients is accepted, the incidence of alloimmunization to
the D antigen in D-negative liver transplant recipients has not been
well defined. With a very active liver transplant programme at our

Immunosuppression and blood management

institution, studying the prevalence of anti-D formation in D-negative
liver transplant recipients receiving D-positive RBCs perioperatively

The detailed immunosuppression protocol has been described previ-

will assist in successful patient blood management.

ously [2]. Briefly, induction immunosuppression included rabbit antithymocyte globulin or basiliximab. The maintenance immunosuppression regimen consisted of tacrolimus, mycophenolate mofetil and

MATERIALS AND METHODS

steroids.
As soon as the blood bank is notified of a potential liver trans-

This was a retrospective study performed at a single large academic

plant, the recipient’s transfusion records are reviewed. If the current

medical centre. The study was approved by our Institutional Review

and previous antibody screening are negative for clinically significant

Board, and informed consent was waived because of the study design.

alloantibodies to RBC antigens, 20 ABO-compatible RBC units will be

Electronic medical records and blood bank files for all 1052 consecu-

allocated for the recipient. If clinically significant alloantibodies were

tive patients who underwent orthotopic liver transplantation (OLT)

identified historically or on the current antibody screening, 30 anti-

with or without other organ transplants at Henry Ford Hospital in

gen-negative serologically cross-matched RBC units were allocated.

Detroit, Michigan, from January 2007 through December 2017 were

Ideally, blood would be stocked 24 h in advance of the day of trans-

reviewed. Patients were identified through the Liver Transplant Insti-

plant; however, blood bank is notified 6–12 h before most scheduled

tute database. The transfusion records of D-negative OLT patients

liver transplants. Our blood bank utilized leukoreduced RBCs collected

were reviewed for perioperative RBC transfusions. The perioperative

by our blood supplier; we would start issuing irradiated units on the

3
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day of transplant. The ABO group of each RBC unit and the RhD type

perioperatively was 19 (range 2–77 units), while the median number

of units labelled as D-negative were confirmed by the Henry Ford

of D-positive RBC units transfused was 7 (range 1–66 units). None of

Hospital blood bank before going into inventory. The decision to

the patients received Rh immune globulin prophylaxis. At the time of

transfuse D-positive RBC units to D-negative patients was based on

OLT, none of the patients had clinically significant RBC alloantibodies

both demand and inventory of D-negative RBC units in the

through antibody screening or a history of alloimmunization to RBC

blood bank.

antigens. There was no evidence of D alloimmunization in any patient

Intraoperative blood product transfusion was managed by the
anaesthesiologist;

transfusion

was

dictated

by

the

patient’s

haemodynamic status, intraoperative course, blood loss and oozing

after a median serologic follow-up of 49.5 months (range 31 days to
127.7 months). The average number of antibody screening post OLT
was 7.29.

from the surgical field, and laboratory testing, mostly haemoglobin,

We had 14 D-negative patients (14/155 = 9.0% of all D-negative

platelet count, prothrombin time and activated partial thromboplastin

liver transplant recipients) who had D alloimmunization before trans-

time. Cell salvage and antifibrinolytics were utilized, as needed. The

plant; none of these patients was transfused with D-positive blood at

criteria for pre- and post-operative blood transfusion were referenced

our institution before alloimmunization.

from current AABB clinical practice guidelines [8–10].

DI SCU SSION
RESULTS
In this study, we reviewed the medical records of OLT patients to
A total of 1052 patients underwent 1099 OLT during the study

determine the prevalence of anti-D formation in D-negative liver

period. The number of transfused D-positive and D-negative patients

transplant recipients receiving D-positive RBCs. During the periopera-

was 809/897 (90.1%) and 140/155 (90.3%), respectively. Of the total

tive period, 17 eligible patients were transfused with a median of

155 D-negative patients, 23 (14.8%) received D-positive RBCs peri-

7 D-positive RBC units (range 1–66 units). After a median serologic

operatively. Two patients did not survive surgery, and four patients

follow-up of 49.5 months, none of the patients developed anti-D

did not have serologic follow-up after 30 days following transfusion

antibodies.

and thus were excluded. The characteristics of the included

OLT has developed throughout the years and become the stan-

17 patients are presented in Table 1. The median age was 54 years

dard of care for advanced liver disease. Although the use of blood

(range 36–67 years); 13 (76.5%) were male. Twelve patients were

components during OLT has considerably decreased over the past

Caucasian.

two decades, transfusion demands are still significant, especially

TABLE 1

The

median

number

of

RBC

units

transfused

Characteristics of the 17 D-negative liver transplant recipients who received D-positive red blood cells (RBCs) perioperatively
No. of D-positive RBCs

No. of D– RBCs

Serological F/Ua

Patient

Age (years)/gender

Ethnicity

Pretransplant diagnosis

1

51/female

AA

HCV cirrhosis

2

0

21.23 months

2

44/male

AA

HCV and alcoholic cirrhosis

3

19

79.43 months

3

36/male

AA

Alcoholic cirrhosis

1

18

31.07 months

4

64/male

White

Autoimmune hepatitis

9

2

8.17 months

5

67/female

White

Liver cirrhosis secondary to NASH

6

53/male

White

Alcoholic cirrhosis

7

48/male

White

8

56/male

White

4

0

127.70 months

30

2

58.87 months

HCV and alcoholic cirrhosis

4

20

53 days

Metastatic neuroendocrine tumour

9

24

113.13 months

9

67/male

White

Alcoholic cirrhosis

25

8

95.23 months

10

59/male

White

Alcoholic cirrhosis

32

4

80.30 months

11

61/female

AA

HCV cirrhosis with HCC

4

4

83.67 months

12

53/female

White

Liver cirrhosis secondary to NASH

10

7

14.20 months

13

63/male

White

HCV cirrhosis with HCC

14

63/male

White

Polycystic liver disease

15

52/male

AA

Liver cirrhosis secondary to NASH

7

9

49.47 months

16

48/male

White

Alcoholic cirrhosis

3

5

4.13 months

17

54/male

White

Alcoholic cirrhosis

66

11

5

10

54.10 months

17

16

5.07 months

Abbreviations: AA, African American; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; NASH, non-alcoholic steatohepatitis.
a
Time from first D-positive RBC transfusion to last antibody screening.

31 days
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during the perioperative period [2]. There is also wide variation in

There is a multitude of factors that could have contributed to the

transfusion rates between transplantation centres, which can be

decision to transfuse D-positive RBC units and to this variation in

attributed to specific patient population, surgical techniques, differ-

transfused units. First, this study was not limited to evaluating

ences

of

intraoperative blood transfusions in OLT. We, instead, reviewed blood

antifibrinolytics and intraoperative blood salvage, among other vari-

transfusions perioperatively, for a period spanning 1 week before OLT

ables [11].

until 2 weeks following OLT. Transfusion needs post OLT surgery can

in

institutional

transfusion

practices,

variable

use

Ensuring an adequate blood supply can be challenging because of

persist because of many factors including coagulopathy, which can

the increased demand, increased number of donor deferrals, and

extend for months following transplantation [14]. In addition, up to

sometimes decreased supply due to weather conditions and

11% of OLT patients would require re-operation for bleeding within

pandemics. Inventory concerns become more pronounced with

2 weeks following OLT, which adds to their transfusion needs [15].

D-negative units, which comprise only 10%–15% of donors. The

Second, although OLT is mostly well planned, some cases are rela-

Rhesus (Rh) blood group is the second most clinically important sys-

tively urgent with short notification to the blood bank, thus limiting

tem after the ABO system. The D antigen is one of the Rh blood

our preparedness to provide D-negative blood. Evaluating the clinical

group antigens; it is highly immunogenic in healthy subjects as well as

situation of D-negative OLT candidates is crucial in making the deci-

in immunocompromised patients [12, 13]. Knowing the high immuno-

sion to accept these patients for surgery. The decision to switch them

genicity of the D antigen and the risks of delayed haemolytic transfu-

to D-positive RBCs is necessary when the D-negative inventory is lim-

sion reactions, D-negative patients are not usually transfused with D-

ited. Third, the demand for large numbers of RBC units may arise with

positive blood. However, blood banks might be forced to transfuse D-

traumas, massive transfusions and emergency surgeries, along with

negative patients with D-positive blood to preserve their D-negative

OLT cases complicated with intraoperative bleeding. In these situa-

RBC units, which are a scarce resource. Although it is not a common

tions, the decision to switch D-negative OLT patients to D-positive

practice to transfuse D-negative males and females beyond the child-

RBCs in order to save D-negative RBCs for patients with known

bearing age with D-positive blood, this is considered an acceptable

anti-D, females of childbearing age and patients with no blood type

approach when the inventory of D-negative blood is small; however,

on file would be appropriate.

the risks of delayed serologic/haemolytic transfusion reactions should

Ramsey et al. evaluated 19 D-negative liver, heart and heart-lung
transplant recipients who were transfused with D-positive RBCs [16].

be discussed with the treating physicians.
An adequate perioperative supply of D-negative blood for

Anti-D was detected in three liver transplant recipients; however,

D-negative patients undergoing OLT is not always possible. We

anti-D antibodies were detected at 3, 11 and 15 days following trans-

had a total of 23 D-negative OLT patients who were transfused

fusion, which was not convincing of a primary immune response. In

with D-positive blood during the study period, 17 of whom were

another study by Burin des Roziers et al., 20 D-negative OLT recipi-

included in the analysis. All these patients were either males or

ents transfused with D-positive RBCs perioperatively were evaluated

females who were beyond the childbearing age. The decision to

[17]. None of the patients developed anti-D antibodies using the IAT.

transfuse these patients with D-positive blood was dictated by the

Two patients showed weak and transient anti-D reacting only with

increased transfusion needs of these patients (refer to Table 1 for

papain-treated RBCs at 10 and 11 days without any signs of

transfusion needs) and the sub-optimal inventory levels of

haemolysis. Other investigators also have supported the safety of

D-negative blood. This cohort of OLT patients was transfused with

transfusing D-positive RBCs in D-negative patients during OLT sur-

a wide range of D-positive RBC units among the total number of

gery [5, 6, 18]. Table 2 summarizes the studies that evaluated

units transfused.

alloimmunization to the D antigen in D-negative OLT recipients who

T A B L E 2 Summary of studies evaluating the rate of alloimmunization to the D antigen in D-negative orthotopic liver transplantation
recipients transfused with D-positive red blood cells (RBCs)

Study (year published)

Type of transplant

No. of
patients

No. of D-positive
units transfused;
median (range)

F/U period; median
(range), months

Number of patients that developed
anti-D

Tiwari et al. [18]

Liver

21

7 (2–20)

11 (6–90)

None

Burin des Roziers et al. [17]

Liver

20

7 (1–40)

30 (9–120)

2 patients at 10 and 11 days after
transfusion, transient

Casanueva et al. [5]

Liver

17

19 (5–41)

15 (2–70)

None

Ramsey et al. [16]

Liver, heart, heart-lung

19

10 (3–153)

2.5–51; median NA

3 patients at 3, 11 and 15 days after
transfusion

Yuan et al. [6]

Liver

15

9 (2–39)

3.6 (1.7–13.5)

None

Current study

Liver

17

7 (1–66)

49.5 (1–128)

None

Abbreviation: NA, not available.
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were transfused with D-positive blood. The lack of alloimmunization

3.

in D-negative OLT patients receiving D-positive blood can be
explained by the fact that patients are maintained on immunosuppressive protocols to prevent the risk of graft rejection. None of the

4.

patients in our study developed anti-D antibodies on last follow-up.
Transfusion of D-positive RBCs in D-negative patients is unavoid-

5.

able in surgeries such as OLT, which put an enormous pressure on limited blood inventory. Transfusing D-positive units to these patients is

6.

essential to prevent postponing these lifesaving procedures. This also
helps in managing inventory and allocating D-negative units for other
patients in whom the risk of alloimmunization would be higher, for

7.

example, D-negative females of childbearing age. In conclusion, transfusion of D-positive blood to D-negative OLT recipients is acceptable

8.

and safe in the setting of immunosuppression due to the low risk of
alloimmunization.
One of our study limitations relate to its retrospective nature and

9.

being dependent on medical record documentation. The study was
done at a single tertiary-care centre; thus, the results might not be
generalizable to other institutions. In addition, the lack of systematic
screening of OLT patients might have contributed to the relatively

10.

small sample size and decreased serologic follow-up period of some
11.

patients.
In conclusion, this study showed that transfusion of D-positive
RBCs in D-negative OLT recipients is a safe and acceptable practice

12.

perioperatively in the setting of immunosuppression; none of the
patients had alloimmunization to the D antigen following transfusion

13.

of D-positive RBCs. This practice allows the conservation of
D-negative RBC units for other patients in greater need of this
resource.

14.
15.
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